Chosa Oncology names Bill Cronin to lead US commercialization of Platin-DRP

  • Chosa Oncology appointed Bill Cronin to lead its US commercialization effort for Platin-DRP.
  • Cronin previously served as CEO of Dignitana from 2015 to 2022, leading US commercialization of the FDA-cleared DigniCap scalp cooling system.
  • The role centers on building US partnerships with drugmakers, cancer centers, clinical labs, and key opinion leaders ahead of a planned RUO launch.
  • The appointment follows clinical data from the ETOP/EORTC SPLENDOUR study showing 16.9-month median overall survival in Platin-DRP-identified lung cancer patients.
  • Chosa recently established a US presence in Boston as it builds a commercial organization for the US market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 20260709:BIT:7585:0) on July 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.